ReviewJournal of pain research2018
Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice.
Review in Journal of pain research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Innovative Approaches in Managing Chronic Low Back Pain: A Comparative Assessment of Clinical Techniques
Efficacy and Safety Study of Celecoxib / Pregabalin / Vitamin B Fixed Dose Combination Versus Celecoxib + Vitamin B Versus Pregabalin + Vitamin B in the Management of Chronic Low Back Pain Mixed Component
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention.Journal of cancer research and clinical oncology · 2023Pooled it
- Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations.Pain research & management · 2021Pooled it
- Evaluating the effectiveness of nonsteroidal anti-inflammatory drug(s) for relief of pain associated with temporomandibular joint disorders: A systematic review.Clinical and experimental dental research · 2020Pooled it
- Article
- 2-[(2-Methyl-phen-yl)amino]-quinoline-3-carb-oxy-lic acid.IUCrData · 2026Article
- Association of Chronic Pain Severity and NSAID Use with Self-Reported Kidney Risk Indicators: A 1-Year Cohort Study.Juntendo medical journal · 2026Article
- Inhibition of the PKC-TRPV1-SP axis by propolis ameliorates chronic inflammatory pain in mice.Iranian journal of basic medical sciences · 2026Article
- Biocompatible Nitro Group-Based Photosensitizer for AIE, Hypoxia, and Photodynamic Therapy. Experimental and Theoretical Approach.Journal of fluorescence · 2025Article
- Article
- Chronic nonsteroidal anti-inflammatory drug use is associated with increased risk of distal biceps tendon injury.JSES international · 2025Article
- Choosing a nonsteroidal anti-inflammatory drug for pain.Australian prescriber · 2025Review
- Relative effectiveness and gastrointestinal safety of NSAIDs being prescribed for upper respiratory tract infections: an explorative cohort study in primary care.International journal of clinical pharmacy · 2025Article
- Inhibitory Effects of Aspirin and Ibuprofen Overdose on Cholinesterase Activity:Current drug safety · 2025Article
- Genetic and serum biomarkers of NSAID hypersensitivity reactions.Frontiers in pharmacology · 2025Article
- A Swiss Cross-Sectional Study on Patients' Perspectives on Chronic Pain Management, Analgesic Treatment, and Genetic Susceptibility.Journal of pain research · 2025Article
- Combination of Ketorolac Tromethamine and Prednisolone-Loaded PLGA Nanocomposite for Effective Chronic Pain Relief in Mice.International journal of nanomedicine · 2025Article
- Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mice.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- [Construction of a predictive model for postoperative pain relief after microscopic spermatic cord surgery for spermatic cord pain].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Phytochemical profiling, antioxidant, cytotoxic, and anti-inflammatory activities of Plectranthus rugosus extract and fractions: in vitro, in vivo, and in silico approaches.Inflammopharmacology · 2024Article
- Design, Synthesis, and Biological Evaluation of Novel Phenoxy Acetic Acid Derivatives as Selective COX-2 Inhibitors Coupled with Comprehensive Bio-Pharmacological Inquiry, Histopathological Profiling, and Toxicological Scrutiny.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COX2-selective and nonselective (ns) nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for chronic pain management. There are marked differences in the risk of adverse gastrointestinal (GI) and cardiovascular (CV) events among different NSAIDs. In 2017, publication of two randomized controlled trials and an individual patient-data meta-analysis provided robust data on the relative GI and CV tolerability profiles of currently available NSAIDs. The PRECISION study showed similar CV-event rates with celecoxib vs naproxen and ibuprofen, but GI tolerability was better for celecoxib. In the CONCERN study of high-GI-risk patients, celecoxib was associated with fewer adverse GI-tract events than naproxen. The meta-analysis showed no significant difference between celecoxib and ns-NSAIDs in the rate of acute myocardial infarction, and celecoxib was the only COX2-selective NSAID with a lower risk of adverse CV and GI events vs ns-NSAIDs. These data add to the body of knowledge about the relative tolerability of different NSAIDs and were used to propose an updated treatment algorithm. The decision about whether to use an NSAID and which one should be based on a patient's risk of developing adverse GI and CV events. Lower- and upper-GI-tract events need to be considered. Celecoxib has a better lower-GI-tract tolerability profile than ns-NSAIDs plus a proton-pump inhibitor. In addition, the latest data suggest that long-term use of celecoxib 200 mg/day may be appropriate for patients at increased CV risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.